Clene (CLNN)
NASDAQ:CLNN
CLNN Stock Chart & Stats
$5.73
-$0.20(-3.40%)
At close: 4:00 PM EST
$5.73
-$0.20(-3.40%)
Day’s Range― - ―
52-Week Range$2.28 - $13.50
Previous CloseN/A
Volume48.08K
Average Volume (3M)71.92K
Market Cap
$67.49M
Enterprise Value$71.28M
Total Cash (Recent Filing)$5.19M
Total Debt (Recent Filing)$21.67M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
May 13, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding11,778,307
10 Day Avg. Volume87,244
30 Day Avg. Volume71,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue356.42
Enterprise Value/Gross Profit454.04
Enterprise Value/Ebitda-3.30
Forecast
1Y Price Target
$32.25Price Target Upside462.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.89
Revenue Forecast (FY)$240.00K
Bulls Say, Bears Say
Bulls Say
Clinical Biomarker EvidenceReductions in neurofilament light (NfL) and IGFBP7 were associated with improved survival and correlated with other disease-relevant markers, providing clinical biomarker evidence that the therapy may affect disease progression.
Clinical Demand And AccessStrong demand for the expanded access program and a subaward partnership with an academic center signal meaningful real-world interest that could ease clinical adoption and generate supportive real-world data.
Safety And TolerabilityA favorable safety and tolerability profile increases the likelihood clinicians and patients will accept the therapy as an add-on, supporting potential uptake even if clinical improvements are modest.
Bears Say
Financial PerformanceOperating losses and higher-than-expected research and general expenses increase pressure on cash resources and may force program reprioritization or expense reductions.
Funding RiskLimited cash runway creates reliance on additional financing tranches, which could dilute existing shareholders or interrupt development timelines if new funding is delayed.
Research ObjectivityA disclosed potential conflict of interest at the research provider may undermine confidence in analyses and affect investor and regulator interpretation of the program's data.
Clene News
CLNN FAQ
What was Clene’s price range in the past 12 months?
Clene lowest stock price was $2.28 and its highest was $13.50 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is $67.49M.
When is Clene’s upcoming earnings report date?
Clene’s upcoming earnings report date is May 13, 2026 which is in 48 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Mar 12, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.577 by -$0.353.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.62.
How many shares outstanding does Clene have?
Clene has 11,778,307 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.577. Following the earnings report the stock price went up 6.093%.
Which hedge fund is a major shareholder of Clene?
Currently, no hedge funds are holding shares in CLNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.25 (462.83% Upside)
$32.25 (462.83% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 51.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 18.5%
Last 30 Days ▲ 18.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
46.17%
12-Months-Change
Fundamentals
Return on Equity
240.83%
Trailing 12-Months
Asset Growth
-33.68%
Trailing 12-Months
Company Description
Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
CLNN Stock 12 Month Forecast
Average Price Target
$32.25
▲(462.83% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
44.90% Insiders
2.05% Mutual Funds
11.44% Other Institutional Investors
40.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---